Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00002778]
Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00002778]
Bio2RDF identifier
NCT00002778
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00002778
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... chronic myelogenous leukemia.
brief title [clinicaltrials_vocabulary:brief-title]
Sargramostim Following Allogen ...... h Chronic Myelogenous Leukemia
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2010-07-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... approximately 6-10 years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
Philadelphia chromosome negative chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia
accelerated phase chronic myelogenous leukemia
atypical chronic myeloid leukemia
chronic phase chronic myelogenous leukemia
relapsing chronic myelogenous leukemia
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2011-07-19T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00002778
official title [clinicaltrials_vocabulary:official-title]
GRANULOCYTE-MACROPHAGE COLONY ...... T FOR CHRONIC MYELOID LEUKEMIA
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000064783
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2005-02-01T00:00:00Z
secondary id [clinicaltrials_vocabulary:secondary-id]
P01CA015396
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1995-02-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2011-04-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
subject accrual and data analysis is completed.
identifier
clinicaltrials:NCT00002778
title
Sargramostim Following Allogen ...... h Chronic Myelogenous Leukemia
@en
type
label
Sargramostim Following Allogen ...... a [clinicaltrials:NCT00002778]
@en